Ergomed, a UK-based company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, says Neil Clark, current Chief Financial Officer (CFO) has been appointed as Chief Executive of Ergomed’s trading subsidiary PrimeVigilance, a provider of drug safety and medical information services to the pharma and biotech industry. Clark remains a board member of Ergomed.
As a consequence of this change, Stephen Stamp has been appointed as CFO and will join the Ergomed board immediately.
Stamp has more than 30 years of experience in corporate finance and general management in both public and private companies in the UK and the US. He joins Ergomed from US-based AssureRx Health, a personalised medicine and bio-informatics company where he was CFO.
Prior to this Stamp was CFO of EZCORP, a consumer financial services company and Chief Operating Officer and CFO at Xanodyne Pharmaceuticals, a speciality pharmaceutical company.
Stamp also has substantial experience working in UK-listed companies. He was Group Finance Director at Regus and prior to this, Group Finance Director at Shire Pharmaceuticals.
Earlier in his career, Stamp was an investment banker with Lazard in London, advising mainly public companies on cross-border M&A and corporate finance. Prior to Lazard, he worked for KPMG where he qualified as a Chartered Accountant.
